Amarin Corp Plcuk (AMRN) EBT Margin Growth (3y) (2016 - 2026)
Amarin Corp Plcuk (AMRN) EBT Margin Growth (3y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
67.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
2,272.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
3,105.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
304.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-4,669.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-3,220.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1,660.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-3,734.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
377.00 |
| 10 |
Amarin Corp Plcuk |
5.84 Bn |
5.66 Bn |
17.77 Mn |
-247.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-247.00 |
| Dec 31, 2025 |
-11,519.00 |
| Sep 30, 2025 |
-1,202.00 |
| Jun 30, 2025 |
5,012.00 |
| Mar 31, 2025 |
-248.00 |
| Dec 31, 2024 |
2,398.00 |
| Sep 30, 2024 |
-4,177.00 |
| Jun 30, 2024 |
-145.00 |
| Mar 31, 2024 |
-1,461.00 |
| Dec 31, 2023 |
-2,706.00 |
| Sep 30, 2023 |
-2,441.00 |
| Jun 30, 2023 |
-2,561.00 |
| Mar 31, 2023 |
-208.00 |
| Dec 31, 2022 |
8,555.00 |
| Sep 30, 2022 |
-124.00 |
| Jun 30, 2022 |
-6,681.00 |
| Mar 31, 2022 |
338.00 |
| Dec 31, 2021 |
-7,813.00 |
| Sep 30, 2021 |
3,510.00 |
| Jun 30, 2021 |
7,072.00 |
